Molecular Partners AG (OTCMKTS:MLLCF – Get Free Report)’s stock price traded up 11.1% on Thursday . The company traded as high as $5.00 and last traded at $5.00. 700 shares changed hands during trading, an increase of 44% from the average session volume of 485 shares. The stock had previously closed at $4.50.
Molecular Partners Stock Up 11.1 %
The firm’s 50 day moving average price is $5.21 and its 200-day moving average price is $5.88.
About Molecular Partners
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317 which is in Phase I clinical trials, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.
Read More
- Five stocks we like better than Molecular Partners
- What is a Secondary Public Offering? What Investors Need to Know
- Micron Stock Under $100: Seize the AI-Driven Upside
- What Are Treasury Bonds?
- AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025
- The Basics of Support and Resistance
- SolarEdge Stock Climbs Back: Goldman Sachs Sees 40% Upside
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
